You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma

 

Online download statistics by month:

Online download statistics by month: May 2020 to February 2026

AbstractFullPdf
May 2020562562214
Jun 202026926968
Jul 202011911957
Aug 2020646227
Sep 2020747327
Oct 2020474726
Nov 2020343419
Dec 2020394019
Jan 2021666628
Feb 2021474729
Mar 2021686816
Apr 2021464622
May 2021434326
Jun 2021565635
Jul 2021919136
Aug 2021515142
Sep 2021505043
Oct 2021494943
Nov 2021605949
Dec 2021616129
Jan 2022676937
Feb 2022515746
Mar 2022646835
Apr 2022879340
May 2022586037
Jun 2022656929
Jul 2022535827
Aug 2022444518
Sep 2022565841
Oct 2022626332
Nov 2022434741
Dec 2022383915
Jan 2023575717
Feb 202310510523
Mar 2023495019
Apr 2023343414
May 2023323226
Jun 2023313726
Jul 2023444525
Aug 2023454526
Sep 2023596317
Oct 2023525534
Nov 2023373914
Dec 2023424219
Jan 2024565927
Feb 2024868636
Mar 2024949585
Apr 2024656542
May 2024525238
Jun 2024555529
Jul 2024575931
Aug 2024484822
Sep 202447491134
Oct 20244142213
Nov 2024424328
Dec 2024676738
Jan 2025848651
Feb 202518718751
Mar 2025949447
Apr 202511211449
May 2025616345
Jun 2025444540
Feb 2026110
Total446445333519